Oncolys Biopharma Reports First Quarter Loss Amid Economic Uncertainty

Oncolys BioPharma Inc. [4588.T]

TOKYO, May 08 (Pulse News Wire) – Oncolys BioPharma Inc. (4588.T) reported a net loss of ¥414,482 thousand for the quarter ending March 31, 2026, compared to a loss of ¥810,789 thousand in the same period last year.

Revenue was ¥3 thousand, while operating expenses amounted to ¥785,202 thousand. The company's financial position showed total assets decreasing to ¥4,528,277 thousand, down from ¥4,555,879 thousand at the end of the previous fiscal year. Liabilities increased to ¥935,185 thousand, up from ¥555,909 thousand, primarily due to higher borrowings. Shareholders’ equity declined to ¥3,593,091 thousand, reflecting lower retained earnings.

Oncolys highlighted ongoing research and development activities centered around its tumor-dissolving virus OBP-301, which remains a key focus despite economic uncertainties. The company also noted progress in clinical trials for OBP-601, a LINE-1 inhibitor developed in collaboration with Transposon Therapeutics. However, due to shifting priorities towards OBP-301, other projects such as OBP-401 and OBP-801 saw reduced emphasis. Given the unpredictable nature of future events impacting revenue streams, Oncolys decided against providing detailed performance forecasts for the remainder of the fiscal year.

Original Disclosure (PDF)

🟡 Confidence: Standard AI-translated content.